The SAFETY of MEDICINES IN PUBLIC HEALTH PROGRAMMES:

Pharmacovigilance an essential tool



The SAFETY of MEDICINES IN PUBLIC HEALTH PROGRAMMES:

Pharmacovigilance an essential tool

WHO Library Cataloguing-in-Publication Data

The safety of medicines in public health programmes: pharmacovigilance an essential tool.

- 1. Adverse drug reaction reporting systems.
- 2. Drug monitoring.
- 3. Product surveillance, Postmarketing.
- 4. National health programmes.
- I. World Health Organization.

ISBN 92 4 159391 1 (NLM classification: QV 771)

© World Health Organization 2006

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France

The SAFETY of MEDICINES IN PUBLIC HEALTH PROGRAMMES:

Pharmacovigilance an essential tool

World Health Organization





WHO Collaborating Centre for International Drug Monitoring

CONTENTS

Contents		Page
Preface		6
Executive	summary	7
Objectives	5	9
Chapter 1	Introduction	10
Chapter 2	Public health programmes using medicines	12
	2.1 Introduction2.2 The public health environment2.3 Public health programmes for disease control2.4 Future needs of public health programmes	12 13 18 19
Chapter 3	Pharmacovigilance	21
	 3.1 Origins of pharmacovigilance 3.2 Aims 3.3 The cost advantage 3.4 Current practice 3.5 Good pharmacovigilance practice 	21 21 22 22 24
Chapter 4	Effectiveness and risk assessment of therapies	25
	4.1 Effectiveness and risk: benefit and harm4.2 Decision-making in risk situations4.3 Good decision-making practices	25 26 27
Chapter 5	Pharmacovigilance and public health programmes: current situation	30
	5.1 Strengths5.2 Weaknesses	30 31
Chapter 6	Integration of pharmacovigilance into public health programmes	33
	 6.1 Introduction 6.2 Justification 6.3 Requirements for pharmacovigilance in public health 6.4 Spontaneous reporting 6.5 Cohort event monitoring 6.6 Roles and responsibilities 6.7 Where there is no national pharmacovigilance system 6.8 Training and capacity building 6.9 Evaluation of the system 	33 34 35 40 40 41 46 46 48

Chapter 7	Conclusions and recommendations	50
Reference	S	53
Annex 1	Summary table of roles and responsibilities for pharmacovigilance in public health programmes	54
Annex 2	Vaccines example	57
Annex 3	World Health Assembly Resolutions	58
Annex 4	Erice Declaration	59

PREFACE

The Quality Assurance and Safety of Medicines team of the World Health Organization (WHO) aims to assure the safety of medicines by ensuring reliable and timely exchange of information on drug safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug Monitoring. This team is developing a series of publications on safety monitoring of medicinal products. This text on pharmacovigilance in public health programmes was developed in consultation with the WHO Collaborating Centre for International Drug Monitoring and the national pharmacovigilance centres participating in the WHO Programme for International Drug Monitoring. The draft was widely circulated and discussed at two informal consultations with international experts in pharmacovigilance and public health experts.

Sincere thanks for their contributions and critical review of the text are due to the following persons: Dr Z. Ali Gorar, Ms N. Arthur, Dr A. Bentsi-Enchill, Dr D. Coulter, Dr M.R. Couper, Dr P. Duclos, Professor S.A. Edlavitch, Professor I.R. Edwards, Dr P. Folb, Dr S. Gressitt, Ms A. Haq, Dr K. Hartigan-Go, Dr N.A. Kshirsagar, Dr R. Laing, Dr V.K. Lepakhin, Ms Y. Maruyama, Dr B. Mintzes, Professor M. Montagne, Mr S. Olsson, Dr S. Pal, Dr L. Rägo, Dr J. Raine, Professor M. Reidenberg, Mr B. Rowsell, Ms C. Scudamore, Dr R. Soulaymani-Bencheikh, Dr Tagwireyi, Dr P. Trouiller, Dr E. Van Ganse and Dr X. Zhang.

Particular thanks are due to Dr D. Coulter, Dr N.A. Kshirsagar and Dr R. Soulaymani-Bencheikh for their drafting of the original manuscript.

EXECUTIVE SUMMARY

Pharmacovigilance is defined as "the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems".

Pharmacovigilance is an arm of patient care. It aims at making the best use of medicines for the treatment or prevention of disease. No one wants to harm patients, but unfortunately any medicine will sometimes do just this. Good pharmacovigilance will identify the risks and the risk factors in the shortest possible time so that harm can be avoided or minimized. When communicated effectively, this information allows for the intelligent, evidence-based use of medicines and has the potential for preventing many adverse reactions. This will ultimately help each patient to receive optimum therapy, and on a population basis, will help to ensure the acceptance and effectiveness of public health programmes.

Significant harm to a few patients can destroy the credibility, adherence to and success of a programme. Rumours and myths about the adverse effects of medicines can spread rapidly and are difficult to refute in the absence of good data. Pharmacovigilance can provide these data. It can also provide evidence of other types of medicine-related problems including treatment failure, counterfeit medicines, poor quality medicines, interactions between medicine and food and the incorrect use of medicines. Good pharmacovigilance practice can generate the evidence that will inspire public confidence and trust.

Pharmacovigilance incorporates and provides training in the identification of adverse reactions, data collection, processing and analysis. Importantly, these activities allow for the identification of previously unsuspected adverse reactions as well as identification of their effects in pregnant women and in the very young or old, which, for new medicines, are generally unknown. The information collected also provides the tools for the effective management of problems. These include communication and minimization of risk.

In developed countries, the cost of adverse reactions in the general population is very high and under-recognized. Against the background of the high disease burden and malnutrition present in many underdeveloped countries, this cost could be proportionately higher. In any public health programme, a well integrated pharmacovigilance system must

预览已结束,完整报告链接和

https://www.yunbaogao.cn/report/index/report?